Premium
Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one‐yr outcome *
Author(s) -
Woodside Kenneth J,
Ishihara Kanae,
Theisen James E,
Early Marilyn G,
Covert Lesa G,
Hunter Glenn C,
Gugliuzza Kristene K,
Daller John A
Publication year - 2003
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2003.00067.x
Subject(s) - medicine , creatinine , renal function , acute tubular necrosis , hepatitis c , hepatitis , transplantation , kidney , kidney transplantation , bilirubin , gastroenterology , alanine transaminase , liver function tests , liver transplantation , immunology
Abstract: Utilization of hepatitis C seropositive kidney donors remains controversial. We examined the use of hepatitis C seropositive donors for renal transplantation. Data for creatinine, liver function tests, cold ischemia time, and graft and patient survival were analyzed from 20 hepatitis C seropositive recipients receiving cadaveric renal allografts from seropositive donors and were compared with 20 hepatitis C seropositive recipients receiving allografts from seronegative donors. Recipients receiving a kidney from a hepatitis C seropositive donor were on the waitlist for 9.9 ± 1.8 months, compared with 17.8 ± 3.3 months for those receiving a kidney from a seronegative donor (p < 0.05). There were no significant differences in graft or patient survival. Incidences of acute cellular rejection and acute tubular necrosis were similar. There were no significant differences in creatinine, alanine aminotransferase, alkaline phosphatase, or bilirubin values. While there was a significant difference in aspartate aminotransferase at 2 wk and 6 months, these differences were of questionable clinical importance. In conclusion, donor seropositivity for hepatitis C should not preclude renal transplantation into a hepatitis C seropositive recipient and utilization of these organs decreases waitlist time for hepatitis C seropositive recipients.